Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Should Revise Assessment Process After Relenza Review, ABPI Says

Executive Summary

The Association of the British Pharmaceutical Industry is proposing an alternative procedure for the U.K.' s National Institute of Clinical Excellence to follow in its new drug assessments, following NICE's Oct. 8 decision to recommend against prescribing Glaxo Wellcome's Relenza for the 1999 flu season.

You may also be interested in...



Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests

Direct-to-consumer advertising for Roche/Gilead's Tamiflu should emphasize the importance of influenza vaccination, FDA Antiviral Drug Products Division Director Heidi Jolson, MD, said in a memo explaining FDA's rationale for approving the flu treatment.

Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests

Direct-to-consumer advertising for Roche/Gilead's Tamiflu should emphasize the importance of influenza vaccination, FDA Antiviral Drug Products Division Director Heidi Jolson, MD, said in a memo explaining FDA's rationale for approving the flu treatment.

WellPoint Hopes To Curb Relenza Costs By Pushing Flu Vaccination

WellPoint Health Networks is encouraging flu vaccinations in 280,000 letters to members, as part of a campaign to limit use of Glaxo Wellcome's influenza treatment Relenza.

Related Content

UsernamePublicRestriction

Register

PS035011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel